611 related articles for article (PubMed ID: 28099920)
1. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.
Koh J; Kim S; Kim MY; Go H; Jeon YK; Chung DH
Oncotarget; 2017 Feb; 8(8):13762-13769. PubMed ID: 28099920
[TBL] [Abstract][Full Text] [Related]
2. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
4. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
5. Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma.
Mann JE; Smith JD; Birkeland AC; Bellile E; Swiecicki P; Mierzwa M; Chinn SB; Shuman AG; Malloy KM; Casper KA; McLean SA; Moyer JS; Wolf GT; Bradford CR; Prince ME; Carey TE; McHugh JB; Spector ME; Brenner JC
Cancer Immunol Immunother; 2019 Feb; 68(2):213-220. PubMed ID: 30361882
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
7. CD103
Wang P; Huang B; Gao Y; Yang J; Liang Z; Zhang N; Fu X; Li L
Cell Immunol; 2018 Mar; 325():48-55. PubMed ID: 29448979
[TBL] [Abstract][Full Text] [Related]
8. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.
Djenidi F; Adam J; Goubar A; Durgeau A; Meurice G; de Montpréville V; Validire P; Besse B; Mami-Chouaib F
J Immunol; 2015 Apr; 194(7):3475-86. PubMed ID: 25725111
[TBL] [Abstract][Full Text] [Related]
9. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma.
Workel HH; Komdeur FL; Wouters MC; Plat A; Klip HG; Eggink FA; Wisman GB; Arts HJ; Oonk MH; Mourits MJ; Yigit R; Versluis M; Duiker EW; Hollema H; de Bruyn M; Nijman HW
Eur J Cancer; 2016 Jun; 60():1-11. PubMed ID: 27038842
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
11. CD103
Chu Y; Liao J; Li J; Wang Y; Yu X; Wang J; Xu X; Xu L; Zheng L; Xu J; Li L
J Cancer; 2019; 10(21):5234-5243. PubMed ID: 31602274
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral CD103-positive tumour-infiltrating lymphocytes are associated with favourable prognosis in patients with triple-negative breast cancer.
Park MH; Kwon SY; Choi JE; Gong G; Bae YK
Histopathology; 2020 Oct; 77(4):560-569. PubMed ID: 32333690
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma.
Chen K; Zhu Z; Zhang N; Cheng G; Zhang F; Jin J; Wu J; Ying L; Mao W; Su D
Med Sci Monit; 2017 Sep; 23():4619-4632. PubMed ID: 28949934
[TBL] [Abstract][Full Text] [Related]
15. CD103
Xiao Y; Li H; Mao L; Yang QC; Fu LQ; Wu CC; Liu B; Sun ZJ
J Dent Res; 2019 Dec; 98(13):1480-1487. PubMed ID: 31658426
[TBL] [Abstract][Full Text] [Related]
16. Characterization of CD103
Han L; Gao QL; Zhou XM; Shi C; Chen GY; Song YP; Yao YJ; Zhao YM; Wen XY; Liu SL; Qi YM; Gao YF
Cancer Immunol Immunother; 2020 Aug; 69(8):1493-1504. PubMed ID: 32285170
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer.
Rakaee M; Kilvaer TK; Dalen SM; Richardsen E; Paulsen EE; Hald SM; Al-Saad S; Andersen S; Donnem T; Bremnes RM; Busund LT
Hum Pathol; 2018 Sep; 79():188-198. PubMed ID: 29885403
[TBL] [Abstract][Full Text] [Related]
18. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.
Al-Shibli KI; Donnem T; Al-Saad S; Persson M; Bremnes RM; Busund LT
Clin Cancer Res; 2008 Aug; 14(16):5220-7. PubMed ID: 18698040
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
Duhen T; Duhen R; Montler R; Moses J; Moudgil T; de Miranda NF; Goodall CP; Blair TC; Fox BA; McDermott JE; Chang SC; Grunkemeier G; Leidner R; Bell RB; Weinberg AD
Nat Commun; 2018 Jul; 9(1):2724. PubMed ID: 30006565
[TBL] [Abstract][Full Text] [Related]
20. Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.
Teng F; Meng X; Wang X; Yuan J; Liu S; Mu D; Zhu H; Kong L; Yu J
Oncotarget; 2016 Sep; 7(39):64318-64329. PubMed ID: 27602763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
